中华皮肤科杂志 ›› 1986, Vol. 19 ›› Issue (3): 139-141.

• 论著 • 上一篇    下一篇

应用0.02%与0.05%CGP14 458软膏及Dermovate软膏治疗慢性银屑病的多中心双盲法对比观察

G. Blum1, S. J. Yawalkar2   

  1. 1. 瑞士佛尼堡Cantonal医院皮肤科医师;
    2. 瑞士巴塞尔Ciba-Geigy有限公司医学部皮肤科医师
  • 出版日期:1986-06-15 发布日期:1986-06-15

A double-blind mufti-centre comparison of 0.02% and 0.05% CGP 14 458 ointments and dermovate ointment in patients with chronic psoriasis

G. Blum1, S. J. Yawalkar2   

  • Online:1986-06-15 Published:1986-06-15

PDF (PC)

223

赞

摘要： 本文报告了德国及瑞士21位皮肤病专家对336例慢性银屑病患者进行了双盲随机多中心的临床试验.用0.05%CGP14 458、0.02%CGP14 458或Dermovate软青治疗重症慢性银屑病多至25天以后,完全消退或明显进步者分别占90%、77%及80%.在用0.05%、0.02%CGP14 458及Dermovate软膏治疗局部副作用的发生率分别为4%、5%及6%临床上未见系统性副作用.这3种试用药剂在关容上容易接受程度及用法方便方面,实际上相同.0.05%CGP14 458证明较Dermovate软膏更为有效,后者是目前世界上临床应用中最为有效的皮质类固醇局部用药.因此0.05%CGP14 458将为治疗慢性、局限性、重症或顽固皮肤病又提供一种受人欢迎的新武器.

Abstract: A double-blind,randomized multicentre clinical trial was carried cut in 336 patients with chronic psoriasis by 21 dermatologists in Germany and Switzerland.The percentages of patients with severe chronic psoriasis showang cure(complete clearance) or marked improvement following treatment wish 0.05% CGP 14 458 ointment,0.02% GGP 14 458 ointemnt or DermovateR ointment for up to 25 days tvere 90%,77% and 80% respectivciy.Adverse effects were reported at the site of application in 4%,5% and 6% of the patients treated with 0.05% GGP 14 458 ointrnent,0.02% CGP 14 458 ointment and Bermovatc ointment,respectivciy.No clinically detectable sysiemic adveae effects were observed.Cosmetic acceptability and ease of apialication of the three trial preparations were practically identical.0.05% CGP 14 458 proved more effective than Dermovate ointment, the most potent ecrticosteroid topical presently used worldwide in clinical practice.Therefore, 0.05% CGP 14 458 ointiment would be a welcome addition to the therapeutic armamentarium for chronic,localized,severe or recalcitrant dcrmatoses.